Nokia and Samsung sign 5G patent licensing deal

ARTICLE SUMMARY

Nokia announced yesterday that they have signed a multi-year 5G patent cross-licensing deal with Samsung.

authors
No items found.
Related Services
Related Industries

Nokia announced yesterday that they have signed a multi-year 5G patent cross-licensing deal with Samsung.

The deal includes Nokia’s 5G patents, including their Standards Essential Patents (SEPs). This replaces the previous agreement between the companies that expired at the end of 2022.

The main points of the new deal are:

  • It licences Nokia’s fundamental inventions in 5G and other technologies to Samsung
  • Samsung will make royalty payments to Nokia for a multi-year period
  • The agreement started on 1 January 2023

Is this a sign of the times?

This cross-licensing deal between Nokia and Samsung follows other significant patent licensing deals agreed between major players in the wireless telecommunications industry towards the end of 2022. These include deals between Ericsson and Apple and between Huawei and OPPO.

Potter Clarkson’s specialist electronics and communications team includes a number of attorneys with extensive telecoms experience. If we can help you with any issue relating to the protection and commercialisation of innovation in any area of telecommunications, please get in touch.

Related News

Priority patent applications for biotech and chemistry startups

Priority patent applications for biotech and chemistry startups

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

HPV-positive oropharyngeal cancer: prevention to precision treatment

HPV-positive oropharyngeal cancer: prevention to precision treatment

Unlocking the future of cleantech

Unlocking the future of cleantech

Winning at the EPO: Proven specialists in EPO oppositions

Winning at the EPO: Proven specialists in EPO oppositions

Protecting antibody innovations beyond composition claims

Protecting antibody innovations beyond composition claims

HPV vaccine success and the IP opportunities ahead

HPV vaccine success and the IP opportunities ahead

Fake weight-loss medications and new enforcement possibilities

Fake weight-loss medications and new enforcement possibilities

See All News